Caedo Oncology Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 7

Caedo Oncology General Information

Description

Developer of an oncology immunotherapy designed to improve the treatment options for cancer patients. The company's hybridoma technology develops new strategies for monoclonal antibody-based therapy, centered on activating distinct pathways for cell death in cancer cells, enabling patients to receive improved treatment through lead candidates that block checkpoint interactions and induce direct programmed cell death.

Contact Information

Website
www.caedooncology.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Forskningsparken
  • Gaustadalléen 21
  • 0349 Oslo
  • Norway
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • Forskningsparken
  • Gaustadalléen 21
  • 0349 Oslo
  • Norway

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Caedo Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator Completed Generating Revenue
1. Early Stage VC 01-Dec-2022 Completed Generating Revenue
To view Caedo Oncology’s complete valuation and funding history, request access »

Caedo Oncology Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 6

    Pending

  • Expiring in next 12 mo

Caedo Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025533157-A Bivalent cd47-binding proteins Pending 07-Oct-2022
AU-2023357510-A1 Divalent cd47 binding proteins Pending 07-Oct-2022
EP-4598957-A2 Divalent cd47 binding proteins Pending 07-Oct-2022
US-20260234246-A1 Divalent cd47 binding proteins Pending 07-Oct-2022
WO-2024074730-A2 Divalent cd47 binding proteins Inactive 07-Oct-2022 C07K16/2803
To view Caedo Oncology’s complete patent history, request access »

Caedo Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Caedo Oncology Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
ERM Invest Asset Manager Minority
Farvatn Venture Venture Capital Minority
Jac Moe Venture Capital Minority
Sarsia Management Venture Capital Minority
Saturn Invest AS Corporation Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Caedo Oncology FAQs

  • When was Caedo Oncology founded?

    Caedo Oncology was founded in 2020.

  • Where is Caedo Oncology headquartered?

    Caedo Oncology is headquartered in Oslo, Norway.

  • What is the size of Caedo Oncology?

    Caedo Oncology has 3 total employees.

  • What industry is Caedo Oncology in?

    Caedo Oncology’s primary industry is Drug Discovery.

  • Is Caedo Oncology a private or public company?

    Caedo Oncology is a Private company.

  • What is Caedo Oncology’s current revenue?

    The current revenue for Caedo Oncology is .

  • Who are Caedo Oncology’s investors?

    ERM Invest, Farvatn Venture, Jac Moe, Sarsia Management, and Saturn Invest AS are 5 of 7 investors who have invested in Caedo Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process